Chemours (UK) Performance
| 0HWG Stock | 19.08 0.24 1.27% |
The firm shows a Beta (market volatility) of 0.72, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Chemours' returns are expected to increase less than the market. However, during the bear market, the loss of holding Chemours is expected to be smaller as well. At this point, Chemours has a negative expected return of -0.0579%. Please make sure to confirm Chemours' mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to decide if Chemours performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Chemours Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Chemours is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Payout Ratio 0.0219 |
1 | Chemours Prices 600M Senior Notes at 8 percent to Refinance Euro Debt - StockTitan | 11/13/2024 |
2 | Chemours Taps Google Data Center Chief for Board, Boosting AI Cooling Strategy - StockTitan | 01/07/2025 |
3 | Chemours Announces Damin Gumpel as President of Titanium Technologies and Diane Picho as Chief Enterprise Enablement Officer - Marketscreener.com | 01/17/2025 |
| Begin Period Cash Flow | 1.3 B |
Chemours |
Chemours Relative Risk vs. Return Landscape
If you would invest 2,022 in Chemours Co on November 2, 2024 and sell it today you would lose (114.00) from holding Chemours Co or give up 5.64% of portfolio value over 90 days. Chemours Co is generating negative expected returns and assumes 2.7203% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than Chemours, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Chemours Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemours' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Chemours Co, and traders can use it to determine the average amount a Chemours' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0213
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 0HWG |
Estimated Market Risk
| 2.72 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Chemours is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chemours by adding Chemours to a well-diversified portfolio.
Chemours Fundamentals Growth
Chemours Stock prices reflect investors' perceptions of the future prospects and financial health of Chemours, and Chemours fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chemours Stock performance.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0397 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 6.51 B | ||||
| Shares Outstanding | 171.08 M | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 6.03 B | ||||
| Gross Profit | 1.13 B | ||||
| EBITDA | 197 M | ||||
| Net Income | (238 M) | ||||
| Total Debt | 4.23 B | ||||
| Book Value Per Share | 4.40 X | ||||
| Cash Flow From Operations | 556 M | ||||
| Earnings Per Share | 4.45 X | ||||
| Total Asset | 8.25 B | ||||
| Retained Earnings | 1.78 B | ||||
About Chemours Performance
Assessing Chemours' fundamental ratios provides investors with valuable insights into Chemours' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Chemours is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Chemours is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Chemours performance evaluation
Checking the ongoing alerts about Chemours for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Chemours help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Chemours generated a negative expected return over the last 90 days | |
| The company reported the revenue of 6.03 B. Net Loss for the year was (238 M) with profit before overhead, payroll, taxes, and interest of 1.13 B. | |
| Over 81.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: Chemours Announces Damin Gumpel as President of Titanium Technologies and Diane Picho as Chief Enterprise Enablement Officer - Marketscreener.com |
- Analyzing Chemours' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chemours' stock is overvalued or undervalued compared to its peers.
- Examining Chemours' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chemours' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chemours' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chemours' stock. These opinions can provide insight into Chemours' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Chemours Stock Analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.